What the FDA actually said about peptides: inside the July 2026 committee documents

A committee against its own agency

On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed seven peptides for the list of substances 503A compounding pharmacies may use: BPC-157, KPV, TB-500, MOTS-c, Semax, epitalon and emideltide (DSIP)¹. The FDA's introductory document was clear: it proposed that no form of any of the seven "NOT be included"².

A little-noticed detail: every nominator had withdrawn its nomination before the meeting. The FDA wrote that it nonetheless "is electing to proceed with the presentation"². The committee voted in favor of six⁹¹⁰.

The votes

• BPC-157, KPV and TB-500: 8 for, 6 against, 1 abstention⁹.
• MOTS-c: 7–5, 2 abstentions⁹.
• Epitalon: 7–5, 1 abstention. Semax: 8–5¹⁰.
• Emideltide (DSIP): 6 for, 7 against, 1 abstention. The only one rejected¹⁰.

The core problem: what exactly is it?

The technical argument running through all the documents is not just the lack of trials; it is characterization. The FDA described inconsistent naming, no impurity, aggregate or endotoxin data on certificates, and an immunogenicity risk "potentially amplified by aggregation" for injectable peptides²³. The FDA's Russell Wesdyk put it this way: "We've never faced a problem of, 'What is it?'"⁹.

Peptide by peptide, in the FDA's words

• TB-500: "FDA did not find any information in the medical literature where TB-500 was administered to patients". In a fibroblast wound-healing assay at 50 µg/mL it "did not induce wound healing". The FDA also identified no acute or repeat-dose toxicity studies³.
• KPV: "The nomination did not include, and FDA did not find any information on the use of these substances administered in humans"⁴.
• Semax: in mice it "potentiated amphetamine-induced" dopamine release; its antithrombotic effect "raises concern about the risk of bleeding"; there are no human pharmacokinetic studies. It is a registered drug in Russia as nasal drops⁵.
• Epitalon: "has the potential to be carcinogenic", because it activates telomerase and lengthens telomeres⁶.
• Emideltide (DSIP): its action on the opioid system "could lead to development of addiction"; insomnia trials were "inconclusive and at best preliminary"⁷.
• MOTS-c: "the molecular targets through which MOTS-c acts remain unknown", and the FDA identified no clinical studies of the proposed uses and no human exposure data⁸.

Who voted

The official roster shows that several voting members are founders or chief medical officers of private clinics or health companies¹⁴. For critics, that explains the gap between the vote and the technical recommendation; for supporters, it brings the experience of clinicians who see patients already using these products.

What changed and what did not

The vote is non-binding: the FDA considers the committee's recommendations but is not legally bound by them, and it had not issued its final determination as of this writing¹. Meanwhile, the official 503A category list (updated May 2026) keeps ibutamoren (MK-677) and kisspeptin-10 in Category 2¹¹. The FDA has also announced it will consult the committee before the end of February 2027 on GHK-Cu for non-injectable routes¹¹; LL-37, dihexa and PEG-MGF are listed among substances whose nominations were withdrawn, with safety risks described by the agency¹².